Growth Metrics

Tandem Diabetes Care (TNDM) Free Cash Flow (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Free Cash Flow readings, the most recent being $6.9 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 9.52% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.4 million, a 368.72% decrease, with the full-year FY2025 number at -$13.4 million, down 368.72% from a year prior.
  • Free Cash Flow hit $6.9 million in Q4 2025 for Tandem Diabetes Care, down from $16.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $34.4 million in Q3 2022 to a low of -$24.0 million in Q4 2022.
  • Median Free Cash Flow over the past 5 years was $7.3 million (2024), compared with a mean of $4.2 million.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 533.03% in 2021 and later plummeted 340.33% in 2025.
  • Tandem Diabetes Care's Free Cash Flow stood at $19.5 million in 2021, then crashed by 222.57% to -$24.0 million in 2022, then skyrocketed by 147.76% to $11.4 million in 2023, then plummeted by 33.16% to $7.6 million in 2024, then decreased by 9.52% to $6.9 million in 2025.
  • The last three reported values for Free Cash Flow were $6.9 million (Q4 2025), $16.6 million (Q3 2025), and -$15.7 million (Q2 2025) per Business Quant data.